Skip to main content
Premium Trial:

Request an Annual Quote

Drug Safety Whistleblower Wants to Fix FDA. GTO Says, Good Luck!

The International Herald Tribune profiles Steven Nissen, the Cleveland Clinic scientist best known for his early warnings about the safety of Vioxx, long before the drug was taken off the market. Just a few months ago he sounded the alert about diabetes drug Avandia, and he is now rumored to be eyeing a post at FDA. (In an interview, Nissen recently said, "I want to fix the FDA.") According to the article, "By digging deeply into companies' own clinical trial data information that used to be available only to U.S. drug regulators who did not always mine it as aggressively Nissen is among a new cadre of activist scientists demanding greater vigilance on drug safety."

Which leaves us at GTO wondering, if Nissen can track this information to come up with safety warnings for these drugs, why isn't everyone doing the same thing?


The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.